Synchron BCI Pivotal Trial: Endpoint and Reimbursement Path

Brain-computer interface signal path leading to a reimbursement icon, representing how Synchron's pivotal trial endpoint choice determines BCI reimbursement.

Synchron’s $200 million Series D, closed November 6, 2025, committed the company to one specific deliverable: a pivotal trial in 2026. The company has navigated a decade of neuroengineering to get here — the endovascular Stentrode approach, the SWITCH and COMMAND feasibility studies, FDA IDE approval, Apple HID integration, and a Cognitive AI division. What … Read more